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• Strong evidence of the effectiveness of opioid substitution therapy (OST) in reducing HIV transmission among PWID but less known about its impact on HCV transmission
• Despite increasing evidence of the protective effects of OST in combination with other interventions, a recent systematic review concluded there was insufficient evidence of the effectiveness of OST alone in preventing HCV infection in PWID
BACKGROUND
• Good coverage of harm reduction initiatives among PWID in Australia
• Low and sustained HIV prevalence and incidence • High HCV prevalence and incidence
• 50%-60% of needle and syringe program (NSP) attendees nationwide test HCV Ab+ (1995 Ab+ ( -2014 • HCV incidence rate of 44.1/100 PY observed in a communitybased cohort of PWID in South West Sydney (1999 Sydney ( -2002 • Decline in HCV infection at the population level over last decade but no recent data to assess whether this is related to increased prevention coverage or reduced risk among PWID.
The HITS-c Study

AIMS
•Estimate HCV incidence in the Hepatitis Incidence and Transmission Study -community (HITS-c) •Identify risk and protective factors associated with incident infection, including NSP and OST (methadone/buprenorphine/suboxone). 
The HITS-c Study
METHODS METHODS
• Data collected at screening and baseline visits on a range of demographic characteristics, injecting and sexual risk behaviour
• Composite variable was created to directly assess proportion of participants potentially eligible for, but not currently receiving, OST:
• Reference: those specifying opioids as "main drug injected in the last 6 months" (predominantly heroin but also methadone, buprenorphine, morphine or oxycodone) and indicating "OST in the last 6 months"
• Compared to: those who had mainly injected opioids and indicated no OST in the last six months, and those who had mainly injected a non-opioid drug and indicated no OST. 
The HITS-c Study Oct 2011
Screened 268 Anti-HCV (%) 166 (37%)
Enrolled 156 Median age at enrolment (years) 27
Female (%) 24
Born in Australia (%) 79 CALD Background (%) 30 F/T work or study (%) 15
Lived 3+ places last 6 months (%) 37
Median age first injected (years) 20
Main drug injected -heroin (%)* 52
Daily or more frequent injection (%)* 23
Receptive syringe sharing* 14
Current drug treatment (%) 31
Prison last year (%) 20
Characteristics of PWID screened for HITS-c
The HITS-c Study RESULTS: Survival curve for progression to primary HCV infection 
OST Protects Against HCV in PWID: The HITS-c Study
CONCLUSIONS
• First community-based prospective cohort study to observe an independent protective effect of OST against HCV infection among heroin injectors not on OST
• Declining HCV incidence likely reflects: 1. A decrease in the size of the PWID population, resulting from changes in the drug market and reduced initiation to injecting
2. An increase in the number of Australians receiving OST, which has almost doubled since 1998 from 1.3 to 2.1 per 1,000 population
• These two factors -a decrease in the PWID population and a concurrent increase in OST coverage -are the likely key drivers of the lower incidence of HCV observed in the current study.
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CONCLUSIONS
• Other non-OST prevention and education initiatives, such as innovative health service delivery models, remain essential
• Despite recent advances in DAA therapies and the potential impact of these new agents on trends in HCV incidence, barriers to access and prohibitive costs mean that uptake by PWID is likely to remain low in the short to medium term.
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